A total of 24 adult patients with type 2 diabetes, on insulin or oral agents, with a body mass index of 25-40kg/m² and with an A1C of less than or equal to 9% were included in the open label, dose escalation crossover trial.
PAZ320 is a non-systemic chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose.
Boston Therapeutics chairman and chief executive officer David Platt said the pre-clinical models demonstrated significant reductions of post-meal elevation of glucose with PAZ320.
"It is important to manage glucose levels given the many complications that result from uncontrolled diabetes. We are hopeful that PAZ320 will help the millions of people who have high blood sugar and diabetes," Platt added.
The interim data analysis of the Phase ll trial reported no serious adverse events from PAZ320.
The company anticipates reporting Phase ll final results by September 2012.